Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral reboundsActivity shown in Paxlovid®-ineligible ...
Neurosense Therapeutics Ltd. ( ($NRSN) ) has shared an announcement. On December 22, 2025, NeuroSense Therapeutics reported that a safety analysis ...
Background Out-of-hours primary care (OOH-PC) services are complex clinical environments where suboptimal care may occur.
NeuroSense (NRSN) reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled ...
Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 ...
Objective To determine whether a full-scale randomised control trial (RCT) assessing the efficacy and cost-effectiveness of a ...
Herrington Management today announced the publication of an independent brief reviewing recent World of Hyatt points redemption patterns and planning considerations for award travel. The analysis ...
Cryptopolitan on MSNOpinion
Crypto Media at a Crossroads: Why Deep Research Matters More Than Ever
Cryptopolitan launches institutional-grade crypto analysis to combat the industry's aggregation crisis. Discover deep ...
Digital twins began as static digital models used primarily for visualization and design. The review shows that they have ...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion of ...
Data underpins every aspect of the investment project lifecycle and is essential for policy dialogue. Analyses of congestion patterns or the identification of infrastructure gaps are the kindling that ...
Objective To examine household-level patterns of self-reliance among forcibly displaced and host populations using the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback